Why the study?
Whether fentanyl can directly negate or reduce the inhibitory effect of P2Y12 receptor antagonists on platelet function had not been established.
Does fentanyl directly activate platelets, potentiate ADP response, or diminish sensitivity to prasugrel metabolite in healthy volunteer blood in vitro?
Does fentanyl directly activate platelets, potentiate ADP response, or diminish sensitivity to prasugrel metabolite in healthy volunteer blood in vitro?
Fentanyl does not directly impair platelet responsiveness to prasugrel metabolite in vitro, suggesting that delayed P2Y12 inhibitor effects in PCI patients are likely due to impaired intestinal absorption rather than direct platelet interactions.
Answers are grounded in this paper and cite their sources.
No direct fentanyl effect on platelet activation or prasugrel metabolite sensitivity in vitro; leaves open absorption delay as sole mechanism for clinical P2Y12 interactions.
Background Clinical trials indicate that fentanyl, like morphine, may impair intestinal absorption and thus decrease the efficacy of oral P2Y12 inhibitors, such as clopidogrel, ticagrelor, and prasugrel. However, the ability of fentanyl to directly negate or reduce the inhibitory effect of P2Y12 receptor antagonists on platelet function has not been established. A series of in vitro experiments was performed to investigate the ability of fentanyl to activate platelets, potentiate platelet response to ADP, and/or diminish platelet sensitivity to prasugrel metabolite (R-138727) in agonist-stimulated platelets. The selectivity and specificity of fentanyl toward major carrier proteins has been also studied. Methods Blood was obtained from healthy volunteers (19 women and 12 men; mean age 40 ± 13 years). Platelet function was measured in whole blood, platelet-rich plasma and in suspensions of isolated platelets by flow cytometry, impedance and optical aggregometry. Surface plasmon resonance and molecular docking were employed to determine the binding kinetics of fentanyl to human albumin, α1-acid glycoprotein, apolipoprotein A-1 and apolipoprotein B-100. Results When applied at therapeutic and supratherapeutic concentrations under various experimental conditions, fentanyl had no potential to stimulate platelet activation and aggregation, or potentiate platelet response to ADP, nor did it affect platelet susceptibility to prasugrel metabolite in ADP-stimulated platelets. In addition, fentanyl was found to interact with all the examined carrier proteins with dissociation constants in the order of 10–4 to 10–9 M. Conclusions It does not seem that the delayed platelet responsiveness to oral P2Y12 inhibitors, such as prasugrel, in patients undergoing percutaneous coronary intervention, results from direct interactions between fentanyl and blood platelets. Apolipoproteins, similarly to albumin and α1-acid glycoprotein, appear to be important carriers of fentanyl in blood.
No takes yet. Share an insight, caveat, or question.
Bednarek et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: